GSK plc (GSK)
NYSE: GSK · IEX Real-Time Price · USD
38.21
-0.17 (-0.44%)
At close: Jul 2, 2024, 4:00 PM
38.35
+0.14 (0.37%)
After-hours: Jul 2, 2024, 7:43 PM EDT
GSK Revenue
GSK had revenue of $39.41B in the twelve months ending March 31, 2024, with 12.47% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $9.44B with 12.72% year-over-year growth. In the year 2023, GSK had annual revenue of $38.39B with 8.66% growth.
Revenue (ttm)
$39.41B
Revenue Growth
+12.47%
P/S Ratio
1.98
Revenue / Employee
$561,304
Employees
70,212
Market Cap
77.91B USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 38.39B | 3.06B | 8.66% |
Dec 31, 2022 | 35.33B | 2.40B | 7.30% |
Dec 31, 2021 | 32.93B | -433.64M | -1.30% |
Dec 31, 2020 | 33.36B | -11.05B | -24.88% |
Dec 31, 2019 | 44.41B | 5.30B | 13.55% |
Dec 31, 2018 | 39.11B | -1.67B | -4.09% |
Dec 31, 2017 | 40.78B | 6.34B | 18.40% |
Dec 31, 2016 | 34.44B | -824.08M | -2.34% |
Dec 31, 2015 | 35.27B | -574.67M | -1.60% |
Dec 31, 2014 | 35.84B | -8.05B | -18.35% |
Dec 31, 2013 | 43.90B | 1.02B | 2.38% |
Dec 31, 2012 | 42.87B | 373.22M | 0.88% |
Dec 31, 2011 | 42.50B | -1.69B | -3.83% |
Dec 31, 2010 | 44.19B | -1.72B | -3.75% |
Dec 31, 2009 | 45.91B | 10.36B | 29.14% |
Dec 31, 2008 | 35.55B | -9.71B | -21.45% |
Dec 31, 2007 | 45.26B | -277.48M | -0.61% |
Dec 31, 2006 | 45.54B | 8.27B | 22.18% |
Dec 31, 2005 | 37.27B | -1.14B | -2.97% |
Dec 31, 2004 | 38.41B | 753.32M | 2.00% |
Dec 31, 2003 | 37.66B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CVS Health | 360.94B |
McKesson | 308.95B |
Cigna | 206.00B |
HCA Healthcare | 66.72B |
Bristol-Myers Squibb Company | 45.53B |
Gilead Sciences | 27.45B |
Becton, Dickinson and Company | 19.72B |
Zoetis | 8.73B |
GSK News
- 5 days ago - GSK stock falls more at London open following RSV vaccination news - Market Watch
- 5 days ago - GSK slides 6% after US CDC narrows scope of RSV shots - Reuters
- 6 days ago - Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations - Market Watch
- 6 days ago - US advisers to consider RSV shots as GSK looks to keep market lead - Reuters
- 14 days ago - Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Benzinga
- 20 days ago - GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease - Business Wire
- 25 days ago - US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk - Business Wire
- 25 days ago - FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach - CNBC